Clinical trial
A Study of the Safety of Rabeprazole Administered to Adults With…
NCT00216489 · Janssen Cilag Pharmaceutica S.A.C.I., Greece, Industry · Completed
Key facts
| NCT number | NCT00216489 |
|---|---|
| Title | A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD) |
| Official title | A Non Interventional Post Authorization Safety Study (PASS) On The Rabeprazole's Administration To Adults With Gastro-Oesophageal Reflux Disease (GORD) |
| Lead sponsor | Janssen Cilag Pharmaceutica S.A.C.I., Greece, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Gastroesophageal Reflux, Heartburn |
| Intervention type | Drug |
| Interventions | rabeprazole sodium |
| Enrollment | 191 |
| Start date | Mar 1, 2003 |
| Completion | Nov 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | Apr 26, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: